Articles by Cynthia Challener, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Cynthia Challener, PhD

Cynthia Challener, PhD


Articles
Change is Afoot at CPhI
October 8, 2014

New investments, expansions, and company rebranding are discussed at CPhI.

CMO Consolidation Continues
October 6, 2014

The last 12 months have seen a number of major acquisitions in the contract manufacturing space.

Specialty API Synthesis Technologies Attract Attention
October 6, 2014

While advances in chemocatalysis for chiral synthesis continue apace, many companies have focused attention on the development of a wider array of enzymes that can be used under commercial manufacturing conditions for the selective conversion of various substrates into more complex intermediates.

Focus on Biosimilars
October 6, 2014

The total market for biopharmaceuticals in 2013 was $36.8 billion according to Kalorama Information. Meanwhile, Frost & Sullivan estimates that the biosimilars market, which it pegged at just $1.2 billion in 2013, will grow to $23 billion in 2019, or more than 20-fold increase.

New Technologies Enhance the Formulation of Highly Potent Drugs
October 2, 2014

Advances in solid and liquid formulation techniques are providing more options.

Fluorination Remains Key Challenge in API Synthesis
October 2, 2014

Safer fluorinating reagents and access to GMP fluorination capabilities remain challenges in API synthesis.

QbD Facilitates Robust API Development
September 29, 2014

With a quality-by-design approach, robust processes can help deliver quality product consistently.

Pharma Outsourcing Driving Need for Cloud-Based Services
September 29, 2014

Multidirectional collaboration is critical for the new pharma business model; cloud-based information services can offer a communications alternative.

New Techniques Advance Asymmetric Synthesis
September 29, 2014

A literature survey underscores the breadth of chiral chemocatalysis and interesting new techniques for the selective preparation of asymmetric compounds.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
8%
All of the above.
42%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here